Prof Sekulovic meets with ecancertv at ESMO 2016 to discuss the regulatory and funding issues that block drug access for thousands of cancer patients, especially in Southern and Eastern Europe.

She describes the reimbursement models of some healthcare funders, and how delays or complications these models limits the suitability of therapies available to many patients.

Prof Sekulovic sets out steps that are being taken to streamline drug access by regulatory bodies and pharmaceutical suppliers, including reforms and stratification of therapies.

For more details, you can read the news story here.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.